Safety and Tolerability of hRPC in Retinitis Pigmentosa

Summary

hRPC is a cell therapy for retinitis pigmentosa. This is a first-in-human, dose escalation study in which participants with retinitis pigmentosa will receive a single subretinal injection of hRPC cells in one eye to evaluate safety and tolerability. Participants will be followed for two years to evaluate the safety and tolerability of hRPC Additional testing will seek to establish any preliminary efficacy from hRPC.

Timeline

Start

2015-12

Primary completion

2022-06

Completion

2023-12

Drugs

Indications